

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
SCIENCE SUBCOMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: MARCH 19, 2021
11 A.M.

REPORTER: BETH C. DRAIN, CA CSR
CSR. NO. 7152

FILE NO.: 2021-06

BETH C. DRAIN, CA CSR NO. 7152

I N D E X

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION	
1. CALL TO ORDER.	3
2. ROLL CALL.	3
3. DISCUSSION OF SELECTION PROCESS FOR REVIEWERS ON THE GRANTS WORKING GROUP.	4
4. PUBLIC COMMENT.	NONE
5. ADJOURNMENT.	21

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MARCH 19, 2021; 11 A.M.

CHAIRMAN STEWARD: ALL RIGHT. WELCOME,
EVERYONE. I'D LIKE TO CALL THE MEETING OF THE
SCIENCE SUBCOMMITTEE TO ORDER. MARIA, COULD YOU
CALL THE ROLL.

MS. BONNEVILLE: SURE. OS STEWARD.

CHAIRMAN STEWARD: HERE.

MS. BONNEVILLE: DEBORAH DEAS. ANNE-MARIE
DULIEGE.

DR. DULIEGE: HERE.

MS. BONNEVILLE: JUDY GASSON. LARRY
GOLDSTEIN.

DR. GOLDSTEIN: HERE.

MS. BONNEVILLE: DAVID HIGGINS.

DR. HIGGINS: HERE.

MS. BONNEVILLE: STEVE JUELSGAARD.

MR. JUELSGAARD: HERE.

MS. BONNEVILLE: SHLOMO MELMED.

DR. MELMED: HERE.

MS. BONNEVILLE: ART TORRES.

MR. TORRES: HERE.

MS. BONNEVILLE: JONATHAN THOMAS.

CHAIRMAN THOMAS: HERE.

MS. BONNEVILLE: KRISTINA VUORI.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. VUORI: HERE.

2 MS. BONNEVILLE: THANK YOU.

3 CHAIRMAN STEWARD: THANK YOU, MARIA. I
4 ASSUME THAT THERE IS GOING TO BE A PRESENTATION.
5 WHO WILL BE TAKING CARE OF THAT?

6 MS. BONNEVILLE: OS, IT'S GIL.

7 CHAIRMAN STEWARD: OKAY. GIL, WELCOME.

8 DR. SAMBRANO: THANK YOU, OS. AND GOOD
9 MORNING, EVERYBODY.

10 I'M GOING TO SHARE MY SCREEN. AND, OS, I
11 DON'T KNOW IF YOU'RE GOING TO BE ABLE TO SEE THIS
12 THROUGH YOUR PHONE.

13 CHAIRMAN STEWARD: YES, I CAN.

14 DR. SAMBRANO: OKAY. GREAT. IT'S ALSO, I
15 THINK, AVAILABLE ON THE AGENDA FOR ANYBODY WHO
16 OTHERWISE CAN'T.

17 SO TODAY WHAT I'M GOING TO DO IS PRESENT
18 AN OVERVIEW OF THE GWG RECRUITMENT AND NOMINATION
19 PROCESS. AND I'M JUST GOING TO BEGIN WITH A BRIEF
20 BACKGROUND ABOUT THE GRANTS WORKING GROUP ITSELF.

21 THE GWG IS RESPONSIBLE, AS YOU KNOW, BY
22 STATUTE FOR EVALUATING THE SCIENTIFIC MERIT OF ALL
23 APPLICATIONS THAT ARE SUBMITTED TO CIRM AND ALSO
24 WITH PROVIDING FUNDING RECOMMENDATIONS THAT COME TO
25 THE ICOC.

BETH C. DRAIN, CA CSR NO. 7152

1 THE GROUP IS COMPOSED OF 15 SCIENTIFIC
2 MEMBERS WHO ARE NOT FROM CALIFORNIA, AND THAT'S
3 BASED ON PROP 14 AND PROP 71, SEVEN PATIENT ADVOCATE
4 MEMBERS OF THE BOARD, AND THE CHAIR OF THE ICOC, WHO
5 SITS IN AN EX-OFFICIO CAPACITY ON THE WORKING GROUP.

6 BUT, OF COURSE, THE GWG HAS TO EVALUATE
7 PROPOSALS FOR SCIENTIFIC MERIT ACROSS ALL OF OUR
8 PILLARS, SO FROM DISCOVERY, TRANSLATION, CLINICAL,
9 EDUCATION, AND INFRASTRUCTURE. AND SO, AS YOU CAN
10 IMAGINE, THE BREADTH OF EXPERTISE THAT'S REQUIRED IS
11 GOING TO BE NECESSARILY VERY LARGE.

12 AND SO IN ORDER TO HAVE AVAILABLE THAT
13 BROAD EXPERTISE AND TO ASSEMBLE GRANTS WORKING GROUP
14 PANELS FOR ALL OF OUR DIFFERENT FUNDING
15 OPPORTUNITIES, CIRM HAS MAINTAINED AND WE INTEND TO
16 GROW A LARGE POOL OF EXPERTS ON THE ORDER OF
17 CURRENTLY ABOUT 250 TO 300 MEMBERS, AND WE MAY NEED
18 MORE. NOW, SINCE THE PANEL CANNOT HAVE MORE THAN 15
19 SCIENTIFIC MEMBERS, WE DRAW THE MOST RELEVANT
20 EXPERTS FROM THAT POOL IN ORDER TO COMPOSE A GROUP
21 THAT BEST MATCHES THE EXPERTISE NEEDS OF THE
22 PORTFOLIO OF PROPOSALS THAT WERE SUBMITTED FOR A
23 GIVEN CYCLE.

24 AND SO IT'S IMPORTANT TO NOTE THAT WE HAVE
25 MULTIPLE CYCLES RUNNING IN PARALLEL AND, THEREFORE,

BETH C. DRAIN, CA CSR NO. 7152

1 MULTIPLE PANELS THAT NEED TO BE ASSEMBLED AT ANY
2 GIVEN TIME. WE ALSO NEED TO ACCOUNT FOR THE
3 AVAILABILITY OF MEMBERS, ANY POSSIBLE CONFLICTS OF
4 INTEREST, AND THE OVERALL WORKLOAD THAT THEY'RE
5 GOING TO GET. JUST AS AN EXAMPLE OF HOW WE CHOOSE
6 EXPERTS, SO FOR OUR CLINICAL PANEL, FOR INSTANCE, WE
7 TYPICALLY INCLUDE REVIEWERS WITH EXPERTISE IN
8 REGULATORY AFFAIRS, MANUFACTURING, PRODUCT
9 DEVELOPMENT, AND THEN RELEVANT CLINICAL DISEASE
10 EXPERTISE, AND WE ALSO ENSURE THAT WE HAVE MULTIPLE
11 EXPERTS THAT CAN CONTRIBUTE TO A GIVEN TOPIC OR
12 SPECIALTY.

13 AND SO IN ASSEMBLING THOSE GRANTS WORKING
14 GROUP PANELS, WE WANT TO ENSURE THAT WE HAVE ENOUGH
15 TO DRAW FROM IN THAT LARGE POOL THAT CAN ADDRESS THE
16 NEEDS OF A PARTICULAR CYCLE AND PROVIDE THOSE VARIED
17 PERSPECTIVES. SO WE ARE LOOKING ESSENTIALLY FOR
18 GAPS IN THAT POOL, WHICH IS AN ONGOING PROCESS FOR
19 US.

20 AND SO IN TERMS OF IDENTIFYING THOSE GAPS,
21 WE LOOK FOR IN THE PANEL MEMBERS THAT CAN FULFILL
22 THE DIVERSITY IN TERMS OF BACKGROUND AND EXPERIENCE
23 FOR OUR PANELS AS WELL AS PROVIDE MULTIPLE
24 SCIENTIFIC PERSPECTIVES, SUCH AS EXPERIENCE FOR THE
25 RELEVANT STAGE OF THERAPY DEVELOPMENT, DISEASE

BETH C. DRAIN, CA CSR NO. 7152

1 INDICATION, THERAPEUTIC APPROACH, MAYBE THE SPECIFIC
2 ACTIVITIES THAT ARE PROPOSED, AND/OR TECHNOLOGIES
3 THAT ARE UTILIZED. IN SOME CASES WE HAVE A LARGE
4 NUMBER OF PROPOSALS WITHIN A SPECIFIC AREA.
5 ENSURING THAT WE HAVE SEVERAL AVAILABLE EXPERTS IN
6 THAT AREA IS ALSO IMPORTANT IN ORDER FOR US TO COVER
7 AND MANAGE WORKLOAD.

8 AND SO THIS DIAGRAM PRESENTS AN OVERVIEW
9 OF THE PROPOSED GRANTS WORKING GROUP RECRUITMENT
10 PROCESS WHICH I WILL GO OVER IN MORE DETAIL IN
11 SUBSEQUENT SLIDES. I'M GOING TO GO THROUGH EACH OF
12 THESE KIND OF FOUR MAJOR ELEMENTS THAT ARE SHOWN.
13 BUT, BRIEFLY, WHEN WE IDENTIFY A NEED OR A GAP IN
14 EXPERTISE, WE MUST FIRST DETERMINE WHO CAN FILL
15 THOSE EXPERTISE NEEDS. AND SO WE CAN GO ABOUT THIS
16 IN A VARIETY OF WAYS THAT I WILL DISCUSS, INCLUDING
17 GETTING RECOMMENDATIONS FROM EXPERTS OR PARTNERS OF
18 OURS.

19 SO ONCE WE IDENTIFY SUCH INDIVIDUALS WITH
20 RELEVANT EXPERTISE, AN ASSESSMENT IS MADE OF THEIR
21 LEVEL OF COMMITMENT TO CIRM. MARIA, I'M GETTING
22 KIND OF LIKE A REPEAT OF WHAT I JUST SAID. I DON'T
23 KNOW WHAT'S GOING ON WITH AUDIO.

24 MS. BONNEVILLE: I THINK IT'S JUST
25 STOPPED. I DON'T HEAR IT AGAIN.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. SAMBRANO: OKAY. GOOD. THANK YOU.
2 ALL RIGHT. SO THEN WE CONDUCT AN
3 ASSESSMENT. AN IMPORTANT PART OF THIS ASSESSMENT IS
4 PARTICIPATION IN THE REVIEW PROCESS ITSELF AS A
5 SPECIALIST REVIEWER THAT DOES NOT VOTE OR SCORE, BUT
6 CONTRIBUTES TO THE DISCUSSION AND EVALUATION OF THE
7 PROPOSALS. AND I'LL TALK A LITTLE BIT MORE ABOUT
8 THAT. NOW, INDIVIDUALS THAT SHOW COMMITMENT TO CIRM
9 AND HAVE DEMONSTRATED KNOWLEDGE AND PROFICIENCY MAY
10 THEN BE NOMINATED FOR MEMBERSHIP INTO THE GWG.

11 AND SO NOMINEES ARE FIRST PROPOSED TO THE
12 CIRM LEADERSHIP TEAM TO DETERMINE IF THEY AGREE THAT
13 THE NOMINEES WILL SERVE THE NEEDS OF CIRM AND WILL
14 ADDRESS OUR NEEDS AND GAPS. AND THEN ONCE WE HAVE
15 AGREEMENT FROM THE CIRM PRESIDENT, THOSE NOMINATIONS
16 ARE BROUGHT TO THE ICOC FOR FINAL APPROVAL.

17 AND THEN JUST AS A NOTE, GWG MEMBERS ARE
18 APPOINTED TO AN INITIAL SIX-YEAR TERM, AND THEN
19 SUBSEQUENT APPOINTMENTS ARE EITHER FOR TWO, FOUR, OR
20 SIX YEARS IN THIRDS AS DESCRIBED IN PROP 14, AND
21 THEN ADDITIONAL TERMS AFTER THAT ARE SIX YEARS EACH.

22 ALL RIGHT. SO LET ME GO INTO A LITTLE
23 MORE DETAIL ON EACH OF THESE ELEMENTS. SO, FIRST,
24 HOW WE GO ABOUT IDENTIFYING EXPERTS AND GETTING
25 RECOMMENDATIONS? WE MAY IDENTIFY RECOGNIZED EXPERTS

BETH C. DRAIN, CA CSR NO. 7152

1 IN THE FIELD OF INTEREST THROUGH SCIENTIFIC
2 LITERATURE, SO SEARCHING FOR EXPERTS WHO HAVE
3 PUBLISHED IN A PARTICULAR AREA, THEIR PARTICIPATION
4 IN RELEVANT SCIENTIFIC MEETINGS, AND MEMBERSHIP IN
5 SCIENTIFIC SOCIETIES OR ORGANIZATIONS. AND WHAT WE
6 LOOK FOR IS AN INDICATION THAT THE SCIENTIST IS A
7 LEADER AND WELL VERSED IN THE FIELD, THE NUMBER AND
8 NATURE OF THE PUBLICATIONS THAT THEY HAVE,
9 INVITATIONS TO SPEAK AND REPRESENT THE TOPIC OF
10 INTEREST AT A RELEVANT MEETING, AND THE ROLE THEY
11 MIGHT HAVE WITHIN THE SCIENTIFIC ORGANIZATION.

12 NOW, IN ADDITION TO THAT, WE ALSO SOLICIT
13 RECOMMENDATIONS FROM OUR CURRENT GRANTS WORKING
14 GROUP MEMBERS AS WELL AS OUR CIRM SCIENTIFIC TEAM.
15 AND AS YOU MIGHT IMAGINE, CIRM PARTICIPATES IN MANY
16 SCIENTIFIC MEETINGS OUTSIDE OF REVIEW. WE HOLD
17 WORKSHOPS, CONFERENCES, WE ALSO ASSEMBLE ADVISORY
18 PANELS SUCH AS THE CLINICAL ADVISORY GROUPS FOR
19 OVERSIGHT OF OUR CLINICAL GRANTS. AND SO IT EXPOSES
20 US TO A VARIETY OF EXPERTS IN THAT WAY FROM WHICH WE
21 CAN ALSO GARNER RECOMMENDATIONS. WE ALSO TAKE
22 RECOMMENDATIONS FROM APPLICANTS OR GRANTEEES AND
23 CERTAINLY INVITE ICOC MEMBERS TO CONTRIBUTE
24 RECOMMENDATIONS WHENEVER THEY HAVE THEM.

25 AND THEN, LASTLY, WE ARE ALSO EXPLORING

BETH C. DRAIN, CA CSR NO. 7152

1 THE POSSIBILITY OF PARTNERSHIPS WITH SCIENTIFIC
2 ORGANIZATIONS AND SOCIETIES WHO CAN SHARE THEIR
3 KNOWLEDGE OF EXPERTS OR RECOMMEND THEIR MEMBERS TO
4 INCREASE OUR OVERALL REACH. OTHER FUNDERS AND
5 ORGANIZATIONS ARE OFTEN LOOKING FOR EXPERTS
6 THEMSELVES, AND SO SHARING IN THIS EFFORT WOULD
7 CERTAINLY BE MUTUALLY BENEFICIAL. AND SO WE ARE
8 ACTUALLY QUITE EXCITED ABOUT THIS IDEA AS IT COULD
9 HELP US IDENTIFY AND GET INSIGHTS ON EXPERTS WHO
10 MIGHT NOT OTHERWISE BE AVAILABLE TO US OR EVEN KNOW
11 ABOUT US. AND WE HAVE BEGUN DISCUSSIONS WITH TWO
12 DIFFERENT ORGANIZATIONS AND PLANS FOR TALKING WITH
13 OTHERS WHO HAVE EXPRESSED INTEREST IN PARTNERING
14 WITH US IN THIS CAPACITY.

15 SO ONCE WE IDENTIFY A POTENTIAL EXPERT,
16 HOW IS IT THAT WE GO ABOUT ASSESSING THEM FOR
17 POSSIBLE GWG NOMINATION? SO AS MENTIONED, WE LOOK
18 AT ELEMENTS SUCH AS THEIR PUBLICATION RECORD,
19 INVITATIONS TO SPEAK AT SCIENTIFIC MEETINGS BUT, IN
20 ADDITION, THEIR ACADEMIC, COMPANY, OR GOVERNMENT
21 POSITION THAT IN SOME WAY DEMONSTRATES LEADERSHIP
22 AND EXPERIENCE IN THE FIELD. WE WILL ALSO LOOK AT
23 ANY AWARDS AND HONORS THAT HIGHLIGHT THEIR
24 SCIENTIFIC ACCOMPLISHMENTS OR RECOMMENDATIONS THAT
25 COME TO US FROM OTHER FUNDING AGENCIES OR SCIENTIFIC

1 SOCIETIES.

2 NOW, IT'S IMPORTANT TO NOTE THAT NOT ALL
3 EXPERTS CAN BE ASSESSED BY THE SAME CRITERIA. SO,
4 FOR EXAMPLE, AN ACADEMIC SCIENTIST COULD BE ASSESSED
5 THROUGH THEIR PUBLICATION RECORD AND ACADEMIC
6 ACHIEVEMENTS; HOWEVER, EXPERTS WITH, SAY, COMPANY OR
7 GOVERNMENT BACKGROUNDS WOULDN'T NECESSARILY HAVE AN
8 EXTENSIVE PUBLICATION RECORD. AND, THEREFORE, WE
9 LOOK FOR OTHER INDICATORS OF THEIR KNOWLEDGE AND
10 EXPERIENCE, SUCH AS HAVING TAKEN THERAPEUTIC
11 PRODUCTS TO MARKET, SUCCESSFULLY SUBMITTED IND'S OR
12 LED CLINICAL TRIALS, HAVING DEVELOPED BROADLY USED
13 MANUFACTURING PROTOCOLS, OR MAYBE REVIEWED
14 SUBMISSIONS FOR THE FDA IF THEY WORKED FOR THE FDA
15 AND SO ON.

16 WE ALSO LOOK TO SEE IF AN EXPERT HAS
17 EXPERIENCE WITH GRANT OR OTHER SIMILAR REVIEWS FOR,
18 SAY, NIH, DEPARTMENT OF DEFENSE, NONPROFIT
19 FOUNDATIONS, OR OTHER SIMILAR ORGANIZATIONS. AND TO
20 US THIS IS AN INDICATOR THAT AN EXPERT WILL BE
21 RELATIVELY FAMILIAR WITH THE GRANTMAKING PROCESS AND
22 PEER REVIEW, AND MAY ALSO BE AN INDICATOR OF THEIR
23 WILLINGNESS TO CONTRIBUTE TO THE SCIENTIFIC REVIEW
24 IN GENERAL. AND AS MENTIONED BEFORE, A CRITICAL
25 PART OF ASSESSING AN EXPERT REVIEWER FOR POSSIBLE

BETH C. DRAIN, CA CSR NO. 7152

1 NOMINATION IS TO FIRST INVITE THEIR PARTICIPATION AS
2 A NONVOTING, NONSCORING SPECIALIST REVIEWER FOR
3 CIRM. AND SO THIS ALLOWS US TO ASSESS THEIR
4 FOLLOW-THROUGH AND UNDERSTANDING OF THE REVIEW
5 PROCESS, INCLUDING THE REVIEW OF ASSIGNED
6 APPLICATIONS, THE COMPLETION OF CRITIQUES, AND FULL
7 PARTICIPATION IN GRANTS WORKING GROUP MEETINGS. WE
8 ALSO LOOK TO SEE IF THE EXPERT DEMONSTRATES
9 KNOWLEDGE, THOUGHTFULNESS, AND THOROUGHNESS WHEN
10 EVALUATING AND DISCUSSING THE PROPOSALS AT THESE
11 MEETINGS.

12 WHEN WE BELIEVE THAT WE HAVE A CANDIDATE
13 OR CANDIDATES THAT HAVE BEEN ASSESSED AS DESCRIBED
14 AND THAT SHOULD BE NOMINATED FOR GWG MEMBERSHIP, WE
15 PROPOSE HAVING THEM VETTED BY THE CIRM LEADERSHIP
16 TEAM. NOW, THE CIRM LEADERSHIP TEAM HAS A CLEAR
17 UNDERSTANDING OF CIRM'S NEEDS, AND THE TEAM, WHICH
18 INCLUDES DR. MILLAN AND LEADERS OF OUR VARIED
19 DEPARTMENTS, IS PRESENT AT GWG REVIEWS TO HEAR THE
20 DELIBERATIONS AND BE WITNESS TO THE COMPETENCY OF
21 OUR REVIEWERS. AND AS SUCH THEY'RE WELL POISED TO
22 CONTRIBUTE AND VET NOMINATIONS TO GWG. THE CIRM
23 TEAM, REVIEW TEAM, WILL PRESENT THEIR BACKGROUND,
24 QUALIFICATIONS, OVERALL PERFORMANCE OF THE EXPERT
25 REVIEWER TO THE LEADERSHIP TEAM TO CONFIRM THEIR

BETH C. DRAIN, CA CSR NO. 7152

1 AGREEMENT ON NOMINATING THESE INDIVIDUALS. AND WITH
2 THE LEADERSHIP TEAM'S ADVICE, THE FINAL LIST OF
3 NOMINATIONS WOULD THEN BE DETERMINED BY DR. MILLAN
4 AND MYSELF.

5 ALL RIGHT. AND LASTLY, ONCE WE HAVE A
6 VETTED LIST OF NOMINEES, WE WILL BRING THOSE NAMES
7 TO THE ICOC FOR FINAL APPROVAL. AND IN THE PAST, WE
8 HAVE PROVIDED A BIOGRAPHY OF EACH NOMINEE THAT
9 INCLUDES A DESCRIPTION OF THEIR EXPERTISE, THEIR
10 TRAINING, AFFILIATIONS, HONORS, AND ACCOMPLISHMENTS,
11 AND SO ON. AND, OF COURSE, WE WILL CONTINUE TO DO
12 SO, BUT IN ADDITION, JUST TO PROVIDE MORE CONTEXT,
13 WE CAN ALSO PROVIDE INFORMATION ON SPECIFIC
14 EXPERTISE GAPS OR NEEDS THAT THE NOMINEE FULFILLS,
15 HOW THE NOMINEE WAS IDENTIFIED, AND THEIR HISTORY OF
16 SERVICE TO CIRM. AND WE CAN ALSO BRING ALONG WITH
17 THAT A RUNNING TOTAL OF OUR EXPERTS IN OUR POOL AS
18 WELL AS THE ACTIVE GWG MEMBERS.

19 SO THAT CONCLUDES THE PRESENTATION.

20 CHAIRMAN STEWARD: THANK YOU, GIL. THAT
21 WAS GREAT. AND JUST LET ME SAY THAT I HAVE BEEN
22 PRIVILEGED TO PARTICIPATE IN THE GRANTS WORKING
23 GROUP MEETINGS NOW FOR SEVERAL YEARS. AND I HAVE TO
24 SAY THAT I'VE BEEN NOTHING BUT IMPRESSED WITH THE
25 WAY THAT YOU AND THE REST OF THE CIRM TEAM HAVE PUT

BETH C. DRAIN, CA CSR NO. 7152

1 TOGETHER THE REVIEW PANELS. IT'S A GROUP OF EXPERTS
2 THAT WERE OBVIOUSLY EXPERT IN THEIR FIELD, EXTREMELY
3 THOUGHTFUL, BUT BROAD IN THEIR CONSIDERATIONS AND
4 PAID VERY CLOSE ATTENTION TO WHATEVER IT IS THAT
5 CIRM DEEMS THE MOST IMPORTANT ASPECTS OF REVIEW,
6 WHICH CHANGES BASED ON THE REVIEW. SO JUST TO SAY,
7 I REALLY WANT TO CALL OUT AND THANK YOU AND THE TEAM
8 FOR ALL THE WORK THAT YOU'VE DONE.

9 SO LET'S OPEN UP THE DISCUSSION TO THE
10 SUBCOMMITTEE MEMBERS. MARIA, I TRUST THAT YOU CAN
11 SEE HANDS RAISED.

12 MS. BONNEVILLE: I CAN. I SEE DR. MELMED.

13 DR. MELMED: A QUICK TECHNICAL QUESTION.
14 AT THE SIX-YEAR TERM, WAS THAT DETERMINED BY THE
15 BALLOT OR WAS IT DETERMINED BY CIRM?

16 DR. SAMBRANO: NO. IT'S UNDER THE RULES
17 OF PROP 71 AND PROP 14. EACH INITIAL TERM IS FOR
18 SIX YEARS.

19 DR. MELMED: SO IT IS BALLOT DETERMINED?

20 DR. SAMBRANO: YES.

21 CHAIRMAN STEWARD: OTHER QUESTIONS OR
22 COMMENTS FROM THE BOARD?

23 DR. DULIEGE: NO. JUST A COMMENT THAT SAY
24 THAT I WANTED TO THANK GIL AND THE CIRM FOR THIS
25 PRESENTATION. IT'S EXTREMELY CLEAR. IT MAKES A LOT

BETH C. DRAIN, CA CSR NO. 7152

1 OF SENSE. I'VE NO COMMENT. IT'S JUST THE RIGHT
2 THING TO DO.

3 CHAIRMAN THOMAS: MARIA, IF I COULD ADD
4 HERE, I JUST WANT TO ECHO WHAT OS SAID, WHICH IS THE
5 GRANT ANALYSIS IS REALLY SORT OF THE MEAT AND
6 POTATOES OF THE WHOLE PROCESS. AND WE HAVE BEEN
7 VERY FORTUNATE SINCE INCEPTION TO HAVE AN
8 EXTRAORDINARY GROUP OF EXPERTS WHO HAVE BEEN ABLE TO
9 ANALYZE THESE GRANTS IN HIGHLY PROFESSIONAL MANNERS
10 AND ARE VERY DEDICATED. I SAT IN ALL OF THESE GRANT
11 MEETINGS LAST ALMOST TEN YEARS NOW AND CONTINUE TO
12 MARVEL AT THE AMOUNT OF TIME AND EFFORT THAT IS PUT
13 INTO EACH OF THE GRANT APPLICATION REVIEWS BY ALL
14 THE MEMBERS OF THE GWG. SO I THINK WE ARE VERY
15 FORTUNATE TO HAVE THEM TO HELP US MAKE THE RIGHT
16 DECISIONS, AND I THINK GIL AND HIS TEAM DO A
17 FIRST-RATE JOB IN VETTING THE POTENTIAL MEMBERSHIP
18 OF THE GWG AND RECOMMENDING TO THE BOARD WHICH
19 MEMBERS WOULD BEST SUIT US AND HELP US. SO I WANT
20 TO JUST SECOND WHAT OS SAID. IT'S BEEN A TERRIFIC
21 ASPECT OF THE ENTIRE CIRM EXPERIENCE.

22 CHAIRMAN STEWARD: THANK YOU.

23 MS. BONNEVILLE: KRISTINA HAS A QUESTION.

24 DR. VUORI: JUST A VERY QUICK QUESTION
25 ABOUT THE PROCESS. I UNDERSTAND THAT WE WILL BE

BETH C. DRAIN, CA CSR NO. 7152

1 VOTING, WHICH I ASSUME IS APPROVING THIS PROCESS IN
2 THE FULL BOARD MEETING. I WAS JUST CURIOUS WHY THAT
3 IS. IS THERE A CHANGE HERE? HOW IS THIS SORT OF AN
4 APPROVAL MATTER? AND HOW WAS THIS HANDLED IN THE
5 PAST? IT SEEMS TO ME THAT THE PROCESS HAS BEEN IN
6 PLACE, SUCCESSFULLY SO, FOR QUITE SOME TIME.

7 DR. SAMBRANO: GO AHEAD, MARIA.

8 DR. MILLAN: I WANTED TO RESPOND ON BEHALF
9 OF THE TEAM. THAT WAS GOING TO BE MY COMMENT. I
10 WANTED TO FIRST, IN RESPONSE TO THAT, JUST TO KIND
11 OF REVIEW WHY WE BROUGHT THIS TODAY. I WANTED TO
12 THANK THE BOARD. ACTUALLY IT WAS DR. MELMED WHO HAD
13 ASKED WHAT THE PROCESS WAS TO ENSURE THAT WE REALLY
14 HAD THE BEST REVIEWERS. I THINK THAT THE GWG AND
15 THE REVIEW TEAM, AS J.T. HAD INDICATED, HAVE REALLY
16 A VERY SOLID REPUTATION FOR REALLY CARRYING OUT A
17 ROBUST AND RIGOROUS REVIEW. SO THAT WAS THE REASON
18 FOR TODAY.

19 THERE ARE CHANGES AND REFINEMENTS TO THIS,
20 KRISTINA, THAT ARE DIFFERENT THAN IN THE PAST. IN
21 ADDITION TO SOME OF THE INFORMATION REGARDING THE
22 SPECIALISTS, THE GWG'S BACKGROUND, THERE'S ALL THESE
23 OTHER STEPS NOW THAT WE FORMALIZED IN TERMS OF HOW
24 THESE GET BROUGHT TO THE BOARD. AND ADDITIONALLY,
25 WE ARE IN CONVERSATIONS WITH LEADERSHIP AT THE

BETH C. DRAIN, CA CSR NO. 7152

1 NATIONAL ACADEMIES AND AT THE ISSCR WHO ARE VERY
2 EXCITED TO BE ABLE TO WORK WITH US IN IDENTIFYING
3 CANDIDATE REVIEWERS. SO IN THIS WAY WE'LL ALSO BE
4 ABLE TO INCREASE THE ROBUSTNESS OF THE POOL FROM
5 WHICH THE REVIEW TEAM WILL BE ABLE TO DRAW FROM.

6 SO WE BELIEVE THAT THIS IS ACTUALLY
7 BUILDING ON WHAT WAS ALREADY IN PLACE. BUT I WANTED
8 TO ALSO SAY, I WANTED TO THANK THE ENTIRE LEADERSHIP
9 TEAM WHO HELPED GIL. TOGETHER WE ALL CAME UP WITH
10 THE PROPOSAL THAT YOU SEE TODAY AS REFINEMENTS TO
11 THE PREVIOUS PROCESS THAT BUILT ON SUCCESS AND
12 BUILDS ON A SOLID RECORD, BUT WE BELIEVE THIS WILL
13 MAKE IT SCALABLE FOR THE DEMAND THAT'S GOING TO BE
14 ON US LAUNCHING THIS NEXT PROPOSITION AND ITS
15 PROGRAMS.

16 DR. VUORI: GREAT. THANK YOU. I KNOW
17 IT'S, I THINK, VERY THOUGHTFUL, VERY IMPRESSIVE
18 PRESENTATION AND PROCESS. CONGRATULATIONS TO THE
19 TEAM FOR PUTTING IT TOGETHER. AND I SUGGEST YOU
20 TRADEMARK IT AND SELL IT TO NATIONAL INSTITUTES OF
21 HEALTH. THEY HAVE A LOT TO IMPROVE IN THEIR
22 PROCESS.

23 DR. MILLAN: THANK YOU SO MUCH.

24 CHAIRMAN STEWARD: OTHER COMMENTS OR
25 QUESTIONS FROM MEMBERS OF THE COMMITTEE?

BETH C. DRAIN, CA CSR NO. 7152

1 MR. JUELSGAARD: I HAD JUST ONE QUICK
2 QUESTION JUST OUT OF CURIOSITY. WHAT PERCENTAGE OF
3 THE GWG POOL, THE OVERALL POOL, COME FROM OUTSIDE OF
4 THE U.S.?

5 DR. SAMBRANO: THAT'S A GREAT QUESTION. I
6 WOULD SAY IT'S UNDER 20 PERCENT, MAYBE 10 TO 15
7 PERCENT MIGHT COME OUTSIDE OF THE U.S.

8 MR. JUELSGAARD: THANK YOU. THANK YOU,
9 GIL.

10 DR. SAMBRANO: SURE.

11 CHAIRMAN STEWARD: OTHER QUESTIONS OR
12 COMMENTS? IF NOT --

13 MS. BONNEVILLE: I THINK SHLOMO HAS
14 ANOTHER QUESTION. IS THAT CORRECT?

15 DR. MELMED: FIRST OF ALL, I CERTAINLY
16 ECHO THE KUDOS TO THE STAFF FOR PRESENTING A VERY,
17 VERY COMPREHENSIVE AND COMPELLING SET OF STATEMENTS.
18 THANK YOU.

19 JUST A CURIOSITY QUESTION FOR US IN
20 CALIFORNIA. HOW MANY OF THE PEOPLE WHO YOU ACTUALLY
21 INVITE TO JOIN OUR GROUP ACTUALLY DECLINE? AND WHY
22 DO THEY DECLINE?

23 DR. SAMBRANO: RIGHT. SO I DON'T HAVE A
24 SPECIFIC NUMBER IN TERMS OF THE PERCENTAGE, BUT WE
25 DEFINITELY GET MANY WHO DECLINE. AND IT'S MOSTLY

BETH C. DRAIN, CA CSR NO. 7152

1 BECAUSE THEY ALREADY FEEL OVER-COMMITTED TO MANY
2 OTHER THINGS THAT THEY HAVE ON THEIR PLATE. SO THE
3 VAST MAJORITY, 99 PERCENT, EXPRESS AN INTEREST IN
4 CONTRIBUTING TO CIRM IN SOME WAY, BUT THOSE THAT
5 DECLINE TYPICALLY SAY I JUST DON'T HAVE ENOUGH TIME
6 REALLY TO PARTICIPATE. AND THAT'S USUALLY THE
7 REASON.

8 CHAIRMAN STEWARD: AND IF I COULD MAYBE
9 JUST ADD TO THAT. I THINK THIS IS A REFLECTION OF
10 THE FACT THAT GIL IS ALWAYS ASKING PEOPLE WHO ARE
11 THE VERY BEST WHO OBVIOUSLY HAVE A TON OF OTHER
12 COMMITMENTS AND OBLIGATIONS AND GET INVITED TO
13 REVIEW FOR ALL KINDS OF DIFFERENT ORGANIZATIONS.
14 SO, AGAIN, IT'S JUST BEEN SUPER TO SEE THE WAY THIS
15 REVIEW GROUP ACTUALLY WORKS. THANK YOU.

16 MS. BONNEVILLE: LARRY, YOU HAD A
17 QUESTION?

18 MR. GOLDSTEIN: YES, I DO. THANK YOU.

19 FIRST OF ALL, I JUST DO WANT TO AGREE THAT
20 THIS IS A TERRIFIC PROCESS YOU GUYS HAVE OUTLINED,
21 AND I THINK IT WILL GENERALLY WORK WELL.

22 I WANT TO RAISE A QUESTION THOUGH. HAVE
23 YOU GIVEN ANY THOUGHT AS TO TRYING TO BALANCE CAREER
24 STAGE IN EACH OF THOSE PANELS? MY EXPERIENCE FROM
25 HAVING SERVED ON A LOT OF THESE PANELS OVER THE

BETH C. DRAIN, CA CSR NO. 7152

1 YEARS IS I THINK THEY WORK BEST WHEN THERE'S A GOOD
2 BLEND OF MORE SENIOR INVESTIGATORS AND SOME
3 INVESTIGATORS THAT ARE, SAY, IMMEDIATELY POST
4 TENURE. YOU GET A SOMEWHAT DIFFERENT PERSPECTIVE
5 FROM EACH GROUP.

6 DR. SAMBRANO: YES. WE HAVE CERTAINLY
7 THOUGHT ABOUT THAT, AND WE DO WANT TO DIVERSIFY FROM
8 DIFFERENT POINTS OF VIEW. SO INCLUDING THE
9 SENIORITY, I THINK THAT BECOMES IMPORTANT AS WELL.
10 SO, YES, ABSOLUTELY.

11 MR. GOLDSTEIN: THANK YOU.

12 MS. BONNEVILLE: OS, I DON'T SEE ANY OTHER
13 QUESTIONS.

14 CHAIRMAN STEWARD: OKAY. THEN, MARIA,
15 COULD YOU INFORM US OF WHAT THE APPROPRIATE COURSE
16 OF ACTION IS? ARE WE AT THIS STAGE RECOMMENDING
17 THIS FOR CONSIDERATION TO THE BOARD OR ANYTHING
18 OTHER THAN THAT?

19 MS. BONNEVILLE: IT WAS AGENDIZED AS JUST
20 A DISCUSSION ITEM. SO COMMENTS WILL BE TAKEN IN AND
21 THEN THE FINAL PRESENTATION WILL BE MADE AT THE
22 BOARD. BUT WE SHOULD DO PUBLIC COMMENT BEFORE WE
23 END THE MEETING.

24 CHAIRMAN STEWARD: EXCELLENT. SO IF THERE
25 ARE NO FURTHER COMMENTS FROM MEMBERS OF THE

BETH C. DRAIN, CA CSR NO. 7152

1 COMMITTEE, ARE THERE ANY PUBLIC COMMENTS?

2 MS. BONNEVILLE: I DO NOT SEE ANY.

3 CHAIRMAN STEWARD: OKAY. SO I THINK,
4 THEN, THAT CONCLUDES THE BUSINESS OF THE SCIENCE
5 SUBCOMMITTEE FOR TODAY. THANK YOU VERY MUCH TO
6 EVERYONE FOR MAKING TIME FOR THIS MEETING, AND WE'LL
7 LOOK FORWARD TO THE PRESENTATION AT THE NEXT BOARD
8 MEETING.

9 MS. BONNEVILLE: THANK YOU SO MUCH,
10 EVERYONE. WE'LL SEE YOU TUESDAY.

11 (THE MEETING WAS THEN CONCLUDED AT 11:27 A.M.)

12
13
14
15
16
17
18
19
20
21
22
23
24
25

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE ZOOM PROCEEDINGS BEFORE THE SCIENCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON MARCH 19, 2021, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 920-3543